2-Amino-6-methylheptane hydrochloride

We are 2-Amino-6-methylheptane hydrochloride CAS:5984-59-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


Product Name: 2-Amino-6-methylheptane hydrochloride
Synonym: (1,5-dimethylhexyl)ammonium chloride; 2-Isooctylamine hydrochloride; DMHA
Cas No.: 5984-59-8
Formula: C8H20ClN
MW: 165.70
EINECS No.:227-798-5

Density: N/A
Boiling point: 155ºC at 760 mmHg
Melting point: 139-140 ºC
Flash point: 48.9ºC

HS Code: 2921199090

UN No.: N.A
Hazard class: Non-dangerous goods
 
Specification

Items of Analysis Standard of Analysis Test Results
Appearance White to off-white powder Conform
Assay(GC) ≥98.0% 98.55%
Loss on Drying ≤1.0% 0.10%
Residue on ignition ≤1.0% 0.16%
Heavy Metals ≤10ppm Confirm
Lead (Pb) ≤1ppm Confirm
Arsenic (As) ≤1ppm Confirm
Cadmium (Cd) ≤1ppm Confirm
Mercury (Hg) ≤0.1ppm Confirm
Total plate count ≤1000cfu/g Confirm
Yeast and mold ≤100cfu/g Confirm
Enterobacteriaceae <100 cfu/g Confirm
E.Coli Absent/10g Negative
CPS Absent/10g Negative
Salmonella Negative Negative
Listeria Negative Negative
Conclusion Conforms to Factory Standard

 
 
Application
Health care product additive.
 
Packaging
25 kg/barrel, can also be packaged according to customer requirements. 
 
Storage
Store in a cool, ventilated warehouse. 
Keep away from fire and heat. 
The temperature should not exceed 37 °C. 

2-Amino-6-methylheptane hydrochloride


Related News: “CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.2-Ethylhexyl 4-(Dimethylamino)benzoate CAS:21245-02-3 “CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.100306-34-1 “CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.D-Arginine Monohydrochloride CAS:627-75-8 CMO services mainly involve four stages: pre-clinical research, clinical trials, sales of patented drugs after listing, and sales of original drug products after patents expire. Its advantages are: lower cost, guaranteed quality, good capacity flexibility, and favorable process Promotion.CMO services mainly involve four stages: pre-clinical research, clinical trials, sales of patented drugs after listing, and sales of original drug products after patents expire. Its advantages are: lower cost, guaranteed quality, good capacity flexibility, and favorable process Promotion.

Related Products
Product Name
1-Chlorocarbonyl-3-Methanesulfonyl-2-Imidazolidinone View Details
2-ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alaninate View Details
2-[(5-bromo-2-methylphenyl)methyl]-5-(4-fluorophenyl)thiophene View Details
5-chlorouracil manufacturer CAS:69094-18-4 Bropol manufacturer 6-(Trifluoromethyl)pyrid-2-one manufacturer Decyl(trimethoxy)silane manufacturer Acetyl Tetrapeptide-2 manufacturer